Clinical trialsCompany release
Allarity extends Phase 2 stenoparib ovarian cancer trial to platinum-refractory and non-RECIST patients
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Tue 17 Nov 2026
Allarity Therapeutics has amended its Phase 2 study of oral PARP/tankyrase inhibitor stenoparib in advanced ovarian cancer, adding two new patient groups evaluated separately from the original cohort.
Allarity Therapeutics announced on 16 November 2026 that it has amended its ongoing Phase 2 trial of stenoparib in advanced ovarian cancer. The drug is an oral dual inhibitor of PARP and tankyrase.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Allarity Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026